Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 24, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
August 12, 2024 16:05 ET | Source: Surrozen, Inc.

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Surrozen Provides Second Quarter 2024 Financial Results and Business Update
June 12, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Surrozen Publishes Study in eLife Demonstrating the Promise of the SWEETS Platform, a Unique TPD Technology, to Further Enhance Wnt Signaling
June 10, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 at the 2024 European Association for the Study of the Liver (EASL) in Milan
June 04, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
May 09, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Surrozen Presents Data Demonstrating the Promise of Antibody Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at ARVO 2024
May 08, 2024 16:05 ET | Source: Surrozen, Inc.

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Surrozen Provides First Quarter 2024 Financial Results and Business Update
April 03, 2024 08:40 ET | Source: Surrozen, Inc.

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
April 01, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
April 01, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules